Regeneron & Telix collaborate on next-gen radiopharmaceuticals
Pharmaceutical companies Regeneron and Telix have announced a collaboration to develop and commercialise next generation radiopharmaceutical therapies. The collaboration will include multiple solid tumour targets from Regeneron’s portfolio of antibodies. The companies also aim to develop radio-diagnostics to support patient selection and treatment response assessment. The deal… Read More